Track: Medical
Christoph Königs
MD, PhD
University Hospital Frankfurt, Department of Paediatrics
Frankfurt, Germany
Shannon Meeks, MD, MBA (she/her/hers)
Professor of Pediatrics
Emory University and Children's Healthcare of Atlanta
Atlanta, United States
The advent of novel non-factor therapies for the treatment of hemophilia A and hemophilia B is changing the treatment landscape. The primary focus will be the new landscape regarding timing of inhibitor development and management strategies after inhibitor development in hemophilia A stressing the importance of education across the community to continue to vigilantly monitor for inhibitors and be prepared to treat persons with inhibitors. In addition the impact of the approval of novel therapies in hemophilia B will be discussed.
Chair: Christoph Königs – University Hospital Frankfurt, Department of Paediatrics
Speaker: Shannon Meeks, MD, MBA (she/her/hers) – Emory University and Children's Healthcare of Atlanta